Tech Company Financing Transactions
NapaJen Pharma Funding Round
NapaJen Pharma closed a $12.4 million Series C funding round on 1/10/2019. Investors included INCJ, Mitsui & Co. and P&E Directions.
Transaction Overview
Company Name
Announced On
1/10/2019
Transaction Type
Venture Equity
Amount
$12,400,000
Round
Series C
Investors
Proceeds Purpose
The funding will be used to complete the Phase 1 clinical development of NJA-730 started in the autumn of 2018 in Australia and prepare for further development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
533 Airport Blvd. 527
Burlingame, CA 94010
USA
Burlingame, CA 94010
USA
Phone
Website
Email Address
Overview
NapaJen Pharma aims to be a game changer in the rising immuno-therapeutics era. NapaJen's Technology makes it possible to deliver low-dose cell-specific highly targeted therapies to first responder immune system cells (dendritic cells and macrophages).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kenji Arima
Chief Financial Officer
Takuma Nakatsuka
Chief Scientific Officer
Kazuo Sakurai
Browse more venture capital transactions:
Prev: 1/10/2019: Sirnaomics venture capital transaction
Next: 1/10/2019: Verato venture capital transaction
Share this article
Where The Data Comes From
We record every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs